Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Hemophilia A, Hemophilia B
Interventions: BAY86-6150, eptacog alfa [activated]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 62 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Sacramento, California • Chattanooga, Tennessee

Conditions: Advanced Solid Tumors
Interventions: ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel; Biological · Drug
Lead sponsor: AskGene Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New York, New York • Pittsburgh, Pennsylvania

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Los Angeles, California • Cincinnati, Ohio

Conditions: Healthy
Interventions: Seltorexant 40 mg, Seltorexant 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Spinal Cord Injury Cervical
Interventions: Active Stimulation, Sham, Training only; Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: KRAS p.G12C Mutant Advanced Solid Tumors
Interventions: sotorasib, Anti PD-1/L1, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 39
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 29 more

Conditions: Medical Oncology
Interventions: Anetumab ravtansine (BAY94-9343), Itraconazole; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: U3-1287, Erlotinib, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more

Conditions: Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Interventions: Patritumab deruxtecan, Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: oxaliplatin, leucovorin calcium, capecitabine, bevacizumab, fluorouracil, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions: PF-06835375, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 17
States / cities: Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: penclomedine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Propionic Acidemia
Interventions: mRNA-3927; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: Not listed
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Stanford, California • Miami, Florida + 11 more

Conditions: Atopic Disorders, Eczema, Atopic
Interventions: Dupilumab, Auto-injector Device, Prefilled syringe; Drug · Device
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 32 more

Conditions: Vestibular Abnormality, Vestibular Nerve Disorders
Interventions: oVEMP - infra-orbital electrode montage, oVEMP - belly-tendon electrode montage; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 20 Years to 99 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alcohol Dependence
Interventions: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1, Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: DS-3939a, Pembrolizumab, Carboplatin, Pemetrexed, DS-1103a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 4 more

Conditions: End Stage Renal Disease
Interventions: Bright light, Dim Light; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Control Capsules, Mars Cocoa Extract Capsules; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 30 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Davis, California

Conditions: Hepatocellular Carcinoma
Interventions: Tocilizumab, Transcatheter Arterial Chemoembolization; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Solid Tumors
Interventions: M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen; Drug · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: DMG, DIPG
Interventions: TAA-T Cell, BBB Disruption; Biological · Device
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 25 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: End Stage Renal Disease
Interventions: Venography, Intravascular ultrasound (IVUS), Image processing; Diagnostic Test · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers, Elevated CRP
Interventions: MRT-8102, Placebo; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more

Search by objective public record fields.

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Combining Spinal Cord Transcutaneous Stimulation and Activity-based Training in Inpatient Rehabilitation to Facilitate Upper Limb Function of Individuals with Acute to Subacute Cervical Spinal Cord Injury

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Test-Retest Reliability of oVEMP's Across Different Electrode Montages

Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse

A Study of DS-3939a in Participants With Solid Tumors

Light Therapy in End Stage Kidney Disease

Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP